bell
The current prices are delayed by 15 mins, login to check live prices.
Natco Pharma Ltd share price logo

Natco Pharma Ltd

(NATCOPHARM)

₹1373.31.81%

as on 04:01PM, 21 Oct 2024

Overview
News
Financials
Q2 2024 Results
Technicals

Natco Pharma Ltd Analyst Rating

based on 11 analysts

HOLD

45.45%

Buy

18.18%

Hold

36.36%

Sell

Based on 11 analysts offering long term price targets for Natco Pharma Ltd. An average target of ₹1348.73

Source: S&P Global Market Intelligence

Natco Pharma Ltd Share analysis

Natco Pharma Ltd price forecast by 11 analysts

Downside of-3.57%

High

₹1675

Target

₹1348.73

Low

₹690

Natco Pharma Ltd target price ₹1348.73, a slight downside of -3.57% compared to current price of ₹1373.3. According to 11 analysts rating.

Source: S&P Global Market Intelligence

Natco Pharma Ltd Performance

  • Day's Low

    Day's High

    ₹1,368.25
    ₹1,408.65
  • 52 Week's Low

    52 Week's High

    ₹724.2
    ₹1,639
1 Month Return-2.9 %
3 Month Return+ 14.01 %
1 Year Return+ 73.36 %
Previous Close₹1,398.65
Open₹1,405.05
Volume3.73L
Upper Circuit-
Lower Circuit-
Market Cap₹25,051.20Cr

Natco Pharma Ltd Key Statistics

P/E Ratio15.31
PEG Ratio0.33
Market Cap₹25,051.20 Cr
P/B Ratio3.05
EPS77.56
Dividend Yield0
SectorPharmaceuticals
ROE25.38

Natco Pharma Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
HOLD₹25,051.20 Cr28.46%0.54₹1,388 Cr₹3,998 Cr
BUY₹15,580.03 Cr2.14%0.52₹602 Cr₹2,851 Cr
BUY₹86,291.18 Cr41.72%0.56₹3,168 Cr₹29,001 Cr
HOLD₹1,02,882.39 Cr63.38%0.64₹3,854 Cr₹19,547 Cr
BUY₹62,070.29 Cr34.6%0.53NANA

About Natco Pharma Ltd

Natco Pharma Limited is an international, RD focused pharmaceutical company that specialises in the development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs). Natco sells products in over 40 countries, and provides contract manufacturing services for other pharmaceutical companies. The company was originally founded in 1981, and has since enjoyed significant growth, launching a variety of products and earning a number of milestones such as a compulsory license from Bayer for its patent protected anticancer drug Nexavar in 2012, and various first-to-market generic drugs including HEPCINAT (generic Sofosbuvir) and Epclusa (a single tablet regimen for the treatment of genotypes 2 and 3 chronic hepatitis C virus HCV infection). In 2021, Natco had 8 launches in the domestic market and acquired Dash Pharmaceuticals LLC in the US. Natco has 8 international subsidiaries, including the Philippines, Australia, Brazil and the US, constantly achieving the first generic to market for a variety of drugs. Natco's ambition for growth looks set to continue in 2022, with a number of new launches planned.

Share Price: ₹1373.30 per share as on 21 Oct, 2024 04:01 PM
Market Capitalisation: ₹25,051.20Cr as of today
Revenue: ₹1,362.60Cr as on June 2024 (Q2 24)
Net Profit: ₹668.50Cr as on June 2024 (Q2 24)
Listing date: 27 Dec, 1995
Chairperson Name: G S Murthy
OrganisationNatco Pharma Ltd
HeadquartersHyderabad
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Natco Pharma Ltd

  • Natco Pharma Targets Growth in Canada and Brazil - 14 Oct, 2024

    Natco Pharma focuses on expanding its presence in Canada and Brazil, aiming for robust growth. The stock is projected to reach a target price of Rs. 1687 in 8 to 10 months.

  • Natco Pharma Shares Rise on Ozempic Settlement - 07 Oct, 2024

    Natco Pharma's shares increased over 4% following a settlement in US patent litigation for the generic version of Ozempic. This development enhances their market entry potential for the diabetes drug, reflecting strong investor optimism.

Insights on Natco Pharma Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, NATCOPHARM stock has moved up by 39.1%

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 17.45% to 17.51% in Sep 2024 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 795.6 Cr → 1.41K Cr (in ₹), with an average increase of 24.8% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, 212.7 Cr → 668.5 Cr (in ₹), with an average increase of 43.6% per quarter

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 24.97% to 26.12% in Sep 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 133.4% return, outperforming this stock by 70.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Torrent Pharmaceuticals Ltd has given 83.8% return, outperforming this stock by 10.4%

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 2.67% to 2.37% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 49.71% to 49.62% in Sep 2024 quarter

Natco Pharma Ltd Financials

Value in ₹ crore
DetailsQ'2 23Q'3 23Q'4 23Q'1 24Q'2 24
Revenue₹1,140.50Cr (-)₹1,031.40Cr (↓9.57%)₹758.60Cr (↓26.45%)₹1,068.30Cr (↑40.83%)₹1,362.60Cr (↑27.55%)
Net Income₹420.30Cr (-)₹369.00Cr (↓12.21%)₹212.70Cr (↓42.36%)₹386.30Cr (↑81.62%)₹668.50Cr (↑73.05%)
Net Profit Margin36.85% (-)35.78% (↓2.90%)28.04% (↓21.63%)36.16% (↑28.96%)49.06% (↑35.67%)
Value in ₹ crore
Details2021202220232024
Total Assets₹4,817.40Cr (-)₹5,105.60Cr (↑5.98%)₹5,564.40Cr (↑8.99%)₹6,762.70Cr (↑21.54%)
Total Liabilities₹726.30Cr (-)₹913.70Cr (↑25.80%)₹862.40Cr (↓5.61%)₹1,170.40Cr (↑35.71%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹422.50Cr (-)₹183.50Cr (↓56.57%)₹57.70Cr (↓68.56%)₹784.40Cr (↑1,259.45%)₹1,196.40Cr (↑52.52%)

Index Inclusions

Nifty MidSmallcap 400

₹20,226.95

-1.55 (-318.85%)

S&P BSE 400 MidSmallCap

₹12,432.98

-1.5 (-189.77%)

S&P BSE 250 SmallCap

₹7,272.82

-1.48 (-109.35%)

BSE Healthcare

₹43,859.93

-0.86 (-378.57%)

Nifty Smallcap 50

₹9,019.85

-1.72 (-157.85%)

S&P BSE SmallCap Select

₹8,293.07

-1.44 (-120.81%)

Nifty Small 100

₹18,797.40

-1.47 (-280.4%)

BSE 500

₹36,661.79

-0.72 (-265.21%)

NIFTY PHARMA

₹23,122.70

-1 (-233.5%)

BSE Small-Cap

₹55,648.96

-1.51 (-851.09%)

S&P BSE AllCap

₹10,734.78

-0.78 (-84.78%)

Nifty 500

₹23,263.25

-0.76 (-177.45%)

Nifty Smallcap 250

₹17,936.30

-1.65 (-300.5%)

Natco Pharma Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
49.62%
-0.18
Foreign Institutions
17.51%
0.32
Mutual Funds
2.37%
-11.37
Retail Investors
26.12%
4.59
Others
4.39%
-15.57

Natco Pharma Ltd Key Indicators

Details20202021202220232024
Earning Per Share (₹)25.1724.249.3239.1977.56
Details20202021202220232024
Return On Equity %12.777.782.5414.3325.38
Details20202021202220232024
Return On Assets %9.929.153.3312.8520.53
Details20202021202220232024
Book Value Per Share (₹)207.34225.84233.62267.06326.99

Natco Pharma Ltd Valuation

Natco Pharma Ltd in the last 5 years

  • Overview

  • Trends

Lowest (11.55x)

January 17, 2024

Today (15.31x)

October 18, 2024

Industry (58.10x)

October 18, 2024

Highest (90.32x)

April 6, 2022

LowHigh

Natco Pharma Ltd Earnings and Dividends

  • Natco Pharma Ltd Earnings Results

    Natco Pharma Ltd’s net profit jumped 59.05% since last year same period to ₹668.50Cr in the Q1 2024-2025. On a quarterly growth basis, Natco Pharma Ltd has generated 73.05% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Natco Pharma Ltd Dividends August,2024

    In the quarter ending June 2024, Natco Pharma Ltd has declared dividend of ₹3 - translating a dividend yield of 0.40%.

    Read More about Dividends

Natco Pharma Ltd Technicals Summary

Bearish

Neutral

Bullish

Bearish

Natco Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.

FAQs on Natco Pharma Ltd

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Natco Pharma Ltd shares.

Natco Pharma Ltd (NATCOPHARM) share price today is ₹1373.3

Natco Pharma Ltd is listed on NSE

Natco Pharma Ltd is listed on BSE

  • Today’s highest price of Natco Pharma Ltd is ₹1408.65.
  • Today’s lowest price of Natco Pharma Ltd is ₹1368.25.

PE Ratio of Natco Pharma Ltd is 15.31

PE ratio = Natco Pharma Ltd Market price per share / Natco Pharma Ltd Earnings per share

Today’s traded volume of Natco Pharma Ltd(NATCOPHARM) is 3.73L.

Today’s market capitalisation of Natco Pharma Ltd(NATCOPHARM) is ₹25051.2Cr.

Natco Pharma Ltd(NATCOPHARMPrice
52 Week High
₹1639
52 Week Low
₹724.2

Natco Pharma Ltd(NATCOPHARM) share price is ₹1373.3. It is down -16.21% from its 52 Week High price of ₹1639

Natco Pharma Ltd(NATCOPHARM) share price is ₹1373.3. It is up 89.63% from its 52 Week Low price of ₹724.2

Natco Pharma Ltd(NATCOPHARMReturns
1 Day Returns
-25.35%
1 Month Returns
-2.9%
3 Month Returns
14.01%
1 Year Returns
73.36%